home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9408c.zip
/
M9480499.TXT
< prev
next >
Wrap
Text File
|
1994-08-20
|
3KB
|
47 lines
Document 0499
DOCN M9480499
TI Development of the anti-gp120 antibody response during seroconversion to
human immunodeficiency virus type 1.
DT 9410
AU Moore JP; Cao Y; Ho DD; Koup RA; Aaron Diamond AIDS Research Center, New
York University School of; Medicine, New York 10016.
SO J Virol. 1994 Aug;68(8):5142-55. Unique Identifier : AIDSLINE
MED/94309181
AB We have studied the development of the antibody response to the surface
glycoprotein gp120 of human immunodeficiency virus type 1 in three
individuals who presented with primary human immunodeficiency virus type
1 infection syndrome. Serum anti-gp120 antibodies were first detected 4
to 23 days after presentation, after p24 antigen and infectious-virus
titers in the peripheral blood had declined manyfold from their highest
values. Whether anti-gp120 antibodies present at undetectable levels are
involved in clearance of viremia remains unresolved. Among the earliest
detectable anti-gp120 antibodies were those to conformationally
sensitive epitopes; these antibodies were able to block the binding of
gp120 monomers to soluble CD4 or to a human monoclonal antibody to a
discontinuous epitope overlapping the CD4-binding site. Some of these
antibodies were type specific to a degree, in that they were more
effective at blocking ligand binding to autologous gp120 than to
heterologous gp120. However, the appearance of these antibodies did not
correlate with that of antibodies able to neutralize the autologous
virus in vitro by a peripheral blood mononuclear cell-based assay.
Antibodies to the V3 loop were detected at about the same time as, or
slightly later than, those to the CD4-binding site. There was a weak
correlation between the presence of antibodies to the V3 loop and
autologous virus-neutralizing activity in two of three individuals
studied. However, serum from the third individual contained V3
antibodies but lacked the ability to neutralize the autologous virus in
vitro, even immediately after seroconversion. Thus, no simple, universal
correlate of autologous virus-neutralizing activity in a peripheral
blood mononuclear cell-based assay is apparent from in vitro assays that
rely on detecting antibody interactions with monomeric gp120 or
fragments thereof.
DE Amino Acid Sequence Antibodies, Monoclonal/IMMUNOLOGY Antibody
Specificity Cells, Cultured Human HIV Antibodies/*IMMUNOLOGY HIV
Envelope Protein gp120/*IMMUNOLOGY HIV Seropositivity/*IMMUNOLOGY
HIV-1/*IMMUNOLOGY Molecular Sequence Data Neutralization Tests
Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).